SCHEMBL1521148

SCHEMBL1521148

O=C(CCCCCCC(=O)c1ccc(N2CCCCC2)cc1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 11/20 1.00
HDAC1 Q13547 10/20 1.00
HDAC6 Q9UBN7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384299 0.88 HDAC1 (1.00) HDAC8HDAC1HDAC6
SCHEMBL1520902 0.88 HDAC8 (0.78) HDAC8HDAC1
SCHEMBL3380502 0.86 HDAC8 (0.76) HDAC8HDAC1
SCHEMBL13039739 0.84 HDAC1 (0.73) HDAC8HDAC1HDAC6
SCHEMBL3380367 0.84 HDAC1 (0.72) HDAC8HDAC1HDAC6
SCHEMBL13039738 0.83 HDAC1 (0.70) HDAC8HDAC1HDAC6
SCHEMBL13039733 0.83 HDAC1 (0.70) HDAC8HDAC1HDAC6
SCHEMBL1520800 0.79 HDAC1 (0.66) HDAC8HDAC1
SCHEMBL12649829 0.78 HDAC1 (0.63) HDAC8HDAC1
SCHEMBL3383995 0.77 HDAC1 (0.63) HDAC8HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160015693-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR AGENCY SCIENCE TECH & RES (SG) 2016-01-21 US disclosed
US-8969313-B2 Methods and compounds for preventing and treating a tumour AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-03-03 US disclosed
US-20110053882-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-03-03 US disclosed
EP-1280764-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2010-11-24 EP disclosed
EP-2217240-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR Agency for Science, Technology And Research (SG) 2010-08-18 EP disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
WO-2009058102-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-05-07 WO disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
EP-1524262-A1 Inhibitors of histone deacetylase Methylgene, Inc. (CA) 2005-04-20 EP disclosed
EP-1280764-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2003-02-05 EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 US disclosed
WO-2001070675-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053882-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR HDAC1, CCAR2, HDAC11 HDAC8 19/4885HDAC1 1/4885HDAC6 25/4885
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 HDAC8 9/4885HDAC1 1/4885HDAC6 6/4885
US-20160015693-A1 METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR HDAC1, HDAC11, CCAR2 HDAC8 15/4885HDAC1 1/4885HDAC6 24/4885
US-20090181971-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC8 9/4885HDAC1 1/4885HDAC6 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.